Great West Life Assurance Co. Can raised its stake in CytomX Therapeutics Inc (NASDAQ:CTMX) by 174.6% in the second quarter, HoldingsChannel.com reports. The fund owned 4,943 shares of the biotechnology company’s stock after buying an additional 3,143 shares during the quarter. Great West Life Assurance Co. Can’s holdings in CytomX Therapeutics were worth $113,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of CTMX. BlackRock Inc. boosted its stake in CytomX Therapeutics by 28.5% in the second quarter. BlackRock Inc. now owns 3,226,401 shares of the biotechnology company’s stock valued at $73,755,000 after acquiring an additional 716,096 shares during the period. Private Advisor Group LLC acquired a new position in CytomX Therapeutics in the second quarter valued at approximately $3,843,000. PointState Capital LP acquired a new position in CytomX Therapeutics in the first quarter valued at approximately $4,381,000. First Trust Advisors LP acquired a new position in CytomX Therapeutics in the second quarter valued at approximately $3,124,000. Finally, FIL Ltd boosted its stake in CytomX Therapeutics by 36.5% in the first quarter. FIL Ltd now owns 429,925 shares of the biotechnology company’s stock valued at $12,231,000 after acquiring an additional 114,962 shares during the period. Institutional investors own 72.03% of the company’s stock.

In related news, insider Sean A. Mccarthy sold 13,052 shares of the business’s stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $23.42, for a total transaction of $305,677.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Sean A. Mccarthy sold 4,497 shares of the business’s stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $25.06, for a total value of $112,694.82. Following the sale, the insider now directly owns 86,560 shares in the company, valued at approximately $2,169,193.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,629 shares of company stock worth $967,572. Corporate insiders own 8.50% of the company’s stock.

A number of brokerages have commented on CTMX. ValuEngine downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, September 17th. SunTrust Banks initiated coverage on CytomX Therapeutics in a report on Friday, June 1st. They set a “buy” rating and a $38.00 price target on the stock. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Tuesday, July 10th. HC Wainwright initiated coverage on CytomX Therapeutics in a report on Thursday, September 13th. They set a “buy” rating and a $32.00 price target on the stock. Finally, BidaskClub cut CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $37.67.

CTMX opened at $18.51 on Tuesday. The company has a market cap of $812.49 million, a PE ratio of -15.58 and a beta of 0.83. CytomX Therapeutics Inc has a twelve month low of $17.02 and a twelve month high of $35.00.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). The business had revenue of $21.34 million for the quarter, compared to the consensus estimate of $16.48 million. CytomX Therapeutics had a negative net margin of 44.46% and a negative return on equity of 74.84%. sell-side analysts forecast that CytomX Therapeutics Inc will post -1.54 EPS for the current year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

See Also: Intrinsic Value and Stock Selection

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics Inc (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.